Moreover, while there was no association between concomitant use of DOACs and antiplatelet agents and the risk of all‐cause mortality among male patients (weighted HR, 0.95; 95% CI, 0.56–1.60; I 2 , 0.00), there was a nonsignificant trend toward an increased risk among female patients (weighted HR, 1.64; 95% CI, 0.98–2.72; I 2 , 0.00).
1
—
—